RELAFEN
LOE ApproachingNDAORALTABLET
Approved
Dec 1991
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
RELAFEN by GSK is clinical pharmacology nabumetone is a non-steroidal anti-inflammatory drug (nsaid) that exhibits anti-inflammatory, analgesic, and antipyretic properties in pharmacologic studies. First approved in 1991.
Drug data last refreshed 2d ago
Mechanism of Action
CLINICAL PHARMACOLOGY Nabumetone is a non-steroidal anti-inflammatory drug (NSAID) that exhibits anti-inflammatory, analgesic, and antipyretic properties in pharmacologic studies. As with other non-steroidal anti-inflammatory agents, its mode of action is not known; however, the ability to inhibit…
Worked on RELAFEN at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.